PCN17 ONCOLOGY DRUGS GAINING FDA APPROVAL FOR LOW SURVIVAL INDICATIONS AND ENTERING FIRST TO MARKET ARE ASSOCIATED WITH LESS MATURE CLINICAL DATA COMPARED TO LATER ENTRANTS